COMP <GO>
NCEL vs JAGX // EV/EBITDA & P/E VALUATION
NewcelX Ltd. (NASDAQ) VS. Jaguar Health Inc. (NASDAQ) • 15-METRIC TALLY: NCEL 1
— JAGX 1
■ METRIC PARITY
LAST: $2.69 (-0.30%) • MKT CAP: $15.5M
valuation
—
LAST: $2.04 (-2.86%) • MKT CAP: $15.9M
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (NCEL VS. JAGX)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | NCEL | JAGX | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 67.20% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -17.84% | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | -60.00% | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | -0.50% | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | -1.50% | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 1/9 | 1/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 42.3 | 39.6 | +2.62 | NCEL | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $15.5M | $15.9M | -$367.0K | JAGX | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | NCEL REV | JAGX REV | NCEL GROSS % | JAGX GROSS % | NCEL FCF | JAGX FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $11.5M | — | 67.2% | -$2.8M | -$23.7M |
| FY 2024 | $0 | $11.7M | — | 83.3% | -$1.1M | -$29.4M |
| FY 2023 | $0 | $9.8M | — | — | -$3.4M | -$33.2M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
NCEL // BETA —
JAGX // BETA —